People
Acting FDA Commissioner Janet Woodcock’s days as interim head of the agency are numbered due to federal regulations. Speculations are rampant on a number of potential choices.
Patients and patient organizations, which have detailed insights in the natural history of a rare disease, should be integral, too.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Pfizer’s exec team is hit with a double whammy as another c-suite leader announces his retirement.
After serving three presidential administrations, Dr. Francis S. Collins is stepping down as director of the National Institutes of Health at the end of the year.
The DOL’s Office of Federal Contract Compliance Programs found that AstraZeneca paid a much lower base salary than similar employees to 23 Hispanic female staff and 295 female employees.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Jose Luis Casero Sanchez took advantage of his position in Goldman Sachs’ “control room” to gain insider knowledge of upcoming transactions, including those for several biopharma companies.
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
Celyad is focusing on advancing chimeric antigen receptor T cell (CAR T) therapies.
PRESS RELEASES